Guardant Health (GH) Stock Chart - Revenue & Earnings | Quarter Chart
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Guardant Health (GH) quarterly earnings & revenue
Guardant Health (GH) reported revenue of $301.67M for Q1 2026, up 48.3% year-over-year, with net income of $-112.08M and diluted EPS of $-0.85.
Over the last four reported quarters, Guardant Health generated $1.08B in revenue and $-433.19M in net income.
Guardant Health's next earnings report is scheduled for July 30, 2026 after market close; analysts estimate EPS of $-0.41.
Guardant Health quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q1 2026 | $301.67M | +48.3% | $-112.08M | $-0.85 |
| Q4 2025 | $281.27M | +39.4% | $-128.49M | $-1.00 |
| Q3 2025 | $265.20M | +38.5% | $-92.72M | $-0.74 |
| Q2 2025 | $232.09M | +30.9% | $-99.90M | $-0.80 |
| Q1 2025 | $203.47M | +20.8% | $-95.16M | $-0.77 |
| Q4 2024 | $201.81M | +30.2% | $-111.01M | $-0.90 |
| Q3 2024 | $191.48M | +33.9% | $-107.75M | $-0.88 |
| Q2 2024 | $177.24M | +29.2% | $-102.63M | $-0.84 |
Guardant Health (GH) — frequently asked questions
When does Guardant Health (GH) report earnings next?
Guardant Health is expected to report earnings on July 30, 2026 after market close. Analysts estimate EPS of $-0.41.
What was GH's revenue last quarter?
Guardant Health reported revenue of $301.67M in Q1 2026, up 48.3% from the same quarter a year earlier.
What was GH's EPS last quarter?
Guardant Health reported diluted EPS of $-0.85 in Q1 2026.
Is Guardant Health profitable?
Guardant Health is currently not profitable, with $-433.19M in net income over the last four reported quarters.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)